Aurora-B Kinase Inhibitors for Cancer Chemotherapy is a research paper published in Mini-Reviews in Medicinal Chemistry (2008). On theSindex it has a DataRank of 0.533. It has been cited 34 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.533
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: R01CA089266
NCI NIH HHS
Grant: R56 CA089266
FWCI
0.51
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 7 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 7 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 8 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 8 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 4 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 5 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 6 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 6 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 5 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 3 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 1 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 2 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 4 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 1 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 2 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2
Additional file 3 of AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2